Heart failure with mid-range ejection fraction: Current evidence and uncertainties
Monaldi Archives for Chest Disease, 2019 Heart failure (HF) with mid-range ejection fraction (HFmrEF) has been conceptualized by the European Society of Cardiology guidelines with the aim of stimulating research to fill a gap in knowledge: whether such a condition exists as a distinct pathophysiological and clinical entity, or it is just a residual category of ejection fraction indeed is ...
Martone R., Marchionni N., Cappelli F.
openaire +6 more sources
Heart failure with mid-range ejection fraction. Where are we today? [PDF]
Българска кардиология, 2021 Дружеството на кардиолозите в България се придържа към Европейските препоръки за сърдечна недостатъчност (СН). Завършилите проучвания и множеството дебати и анализи след 2016 г. са предпоставка за ново ръководство за диагноза и поведение при тези болни. Особен интерес предизвиква т.нар.
Tzvetana Katova
doaj +5 more sources
Heart failure with mid-range ejection fraction: pro and cons of the new classification of Heart Failure by European Society of Cardiology guidelines. [PDF]
ESC Heart Fail, 2020 Currently, the assessment of left ventricular ejection fraction (LVEF) is the cornerstone of the classification of patients with heart failure (HF). The mid‐range LVEF (HFmrEF) category was identified in an attempt to uncover specific characteristics of ...
Branca L, Sbolli M, Metra M, Fudim M.
europepmc +2 more sources
Heart failure with mid-range ejection fraction: Two overlapping entities?
CorSalud, 2019 Heart failure with mid-range ejection fraction: Two overlapping entities?
F. Javier Martín-Sánchez +3 more
openaire +2 more sources
Heart Failure With Mid-range Ejection Fraction: A Distinctive Subtype or a Transitional Stage? [PDF]
Front Cardiovasc Med, 2021 Heart failure with mid-range ejection fraction (HFmrEF) was first proposed by Lam and Solomon in 2014, and was listed as a new subtype of heart failure (HF) in 2016 European Society of Cardiology guidelines. Since then, HFmrEF has attracted an increasing
Zhou Q +7 more
europepmc +2 more sources
Rehospitalization burden and morbidity risk in patients with heart failure with mid-range ejection fraction. [PDF]
ESC Heart Fail, 2020 Aims Heart failure with mid‐range ejection fraction (HFmrEF) has been proposed as a distinct HF phenotype, but whether patients on this category fare worse, similarly, or better than those with HF with reduced EF (HFrEF) or preserved EF (HFpEF) in terms ...
Santas E +9 more
europepmc +2 more sources
Long-term mortality in heart failure with mid-range ejection fraction: systematic review and meta-analysis. [PDF]
ESC Heart Fail, 2022 Aims Heart failure patients with mid‐range ejection fraction (HFmrEF) have overlapping clinical features, compared with patients with reduced ejection fraction (HFrEF) and preserved ejection fraction (HFpEF).
Raja DC +10 more
europepmc +2 more sources
Use of angiotensin receptor blocker is associated with improved 1 year mortality in heart failure with mid-range ejection fraction. [PDF]
ESC Heart Fail, 2021 Aims Current evidence about the effect of angiotensin receptor blocker (ARB) on the outcome of heart failure with mid‐range ejection fraction (HFmrEF) is lacking.
Wang B +6 more
europepmc +2 more sources
Treatment of Heart Failure With Mid-Range Ejection Fraction: A Summary of Current Evidence. [PDF]
Front Cardiovasc Med, 2021 Heart failure (HF) is a complex syndrome causing heavy burden in public health, and the modern objective assessment of it is based on the left ventricular ejection fraction (LVEF). In 2016, the European Society of Cardiology classified the “gray area” in
Ma T, Su Y, Song J, Xu D.
europepmc +2 more sources
Spironolactone use is associated with improved outcomes in heart failure with mid-range ejection fraction. [PDF]
ESC Heart Fail, 2020 Aims Spironolactone has been shown to improve outcomes in patients with heart failure (HF) with reduced ejection fraction (EF). We investigated whether the discharge use of spironolactone could be associated with better long‐term outcomes among patients ...
Enzan N +6 more
europepmc +2 more sources